Bone Marrow-Derived Mesenchymal Stem Cells as Immunosuppressants in Liver Transplantation: A Review of Current Data

Transfusion Medicine Reviews

Volumn 26, Issue 2, 2012, Pages 129-141

  Zhang, Hongyu ^a   Chen, Zhiyu ^a   Bie, Ping ^a  

^a SOUTHWEST HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED LEUKOCYTE CELL ADHESION MOLECULE; B7 ANTIGEN; CD40 ANTIGEN; CD86 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 12P70; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ACUTE LIVER FAILURE; ARTICLE; BONE MARROW DERIVED MESENCHYMAL STEM CELL; CELL CONTACT; CELL FUSION; CELL SURVIVAL; CLINICAL TRIAL (TOPIC); DENDRITIC CELL; END STAGE LIVER DISEASE; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INTERMETHOD COMPARISON; LIVER CANCER; LIVER CELL; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LYMPHOCYTE FUNCTION; MESENCHYMAL STEM CELL; NATURAL KILLER CELL; NONHUMAN; SAFETY; SURVIVAL RATE; SURVIVAL TIME; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TRANSPLANTATION TOLERANCE; TREATMENT INDICATION;

BONE MARROW CELLS; BONE MARROW TRANSPLANTATION; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSION; LIVER TRANSPLANTATION; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STEM CELLS;

EID: 84858276502     PISSN: 08877963     EISSN: 15329496     Source Type: Journal    
DOI: 10.1016/j.tmrv.2011.09.002     Document Type: Article

References (136)

1. Lee W.M., Squires R.H., Nyberg S.L., et al. Acute liver failure: Summary of a workshop. Hepatology 2008, 47:1401-1415.
2. Kim W.R., Biggins S.W., Kremers W.K., et al. Hyponatremia and mortality among patients on the liver-transplant waiting list. N Engl J Med 2008, 359:1018-1026.
3. Hashimoto K., Miller C., Hirose K., et al. Measurement of CD4+ T-cell function in predicting allograft rejection and recurrent hepatitis C after liver transplantation. Clin Transplant 2010, 44:701-708.
4. Seyfert-Margolis V., Feng S. Tolerance: is it achievable in pediatric solid organ transplantation?. Pediatr Clin North Am 2010, 57:523-538.
5. Gierej B., Górnicka B., Wasiutyński A. Role of C3d and C4d complement fragments in the diagnostics of acute allograft rejection after transplantations. Ann Transplant 2009, 14:61-70.
6. Wang C., Tay S.S., Tran G.T., et al. Donor IL-4-treatment induces alternatively activated liver macrophages and IDO-expressing NK cells and promotes rat liver allograft acceptance. Transpl Immunol 2010, 22:172-178.
7. Millán O., Sánchez-Fueyo A., Rimola A., et al. Is the intracellular ATP concentration of CD4+ T-cells a predictive biomarker of immune status in stable transplant recipients?. Transplantation 2009, 88(3 Suppl):S78-S84.
8. Friedenstein A.J., Chailakhjan R.K., Lalykina K.S. The development of fibroblast colonies in monolayer cultures of guinea-pig bone marrow and spleen cells. Cell Tissue Kinet 1970, 3:393-403.
9. Comite P., Cobianchi L., Avanzini M.A. Isolation and ex vivo expansion of bone marrow-derived porcine mesenchymal stromal cells: potential for application in an experimental model of solid organ transplantation in large animals. Bone Marrow Transplant Transplant Proc 2010, 42:1341-1343.
10. Zeddou M., Briquet A., Relic B., et al. The umbilical cord matrix is a better source of mesenchymal stem cells (MSC) than the umbilical cord blood. Cell Biol Int 2010, 34:693-701.
11. Semenov O.V., Koestenbauer S., Riegel M., et al. Multipotent mesenchymal stem cells from human placenta: critical parameters for isolation and maintenance of stemness after isolation. Am J Obstet Gynecol 2010, 202:193.e1-193.e13.
12. De Mattos Carvalhoi A., Alves A.L., Golim M.A., et al. Isolation and immunophenotypic characterization of mesenchymal stem cells derived from equine species adipose tissue. Vet Immunol Immunopathol 2009, 132:303-306.
13. Giovannini S., Brehm W., Mainil-Varlet P., et al. Multilineage differentiation potential of equine blood-derived fibroblast-like cells. Differentiation 2008, 76:118-129.
14. Lanzoni G., Alviano F., Marchionni C., et al. Isolation of stem cell populations with trophic and immunoregulatory functions from human intestinal tissues: Potential for cell therapy in inflammatory bowel disease. Cytotherapy 2009, 11:1020-1031.
15. Kassis I., Zangi L., Rivkin R., et al. Isolation of mesenchymal stem cells from G-CSF-mobilized human peripheral blood using fibrin microbeads. Bone Marrow Transplant 2006, 37:967-976.
16. Karaoz E., Ayhan S., Gacar G., et al. Isolation and characterization of stem cells from pancreatic islet: Pluripotency, differentiation potential and ultrastructural characteristics. Cytotherapy 2010, 12:288-302.
17. Huang G.T., Gronthos S., Shi S. Mesenchymal stem cells derived from dental tissues vs. those from other sources: Their biology and role in regenerative medicine. J Dent Res 2009, 88:792-806.
18. Siepe M., Thomsen A.R., Duerkopp N., et al. Human neonatal thymus-derived mesenchymal stromal cells: Characterization, differentiation, and immunomodulatory properties. Tissue Eng Part A 2009, 15:1787-1796.
19. Kim H.K., Lee Y.S., Sivaprasad U., et al. Muscle-specific microRNA miR-206 promotes muscle differentiation. J Cell Biol 2006, 174:677-687.
20. Haag M., Van Linthout S., Schröder S.E., et al. Endomyocardial biopsy derived adherent proliferating cells-A potential cell source for cardiac tissue engineering. J Cell Biochem 2010, 109:564-575.
21. Hayase M., Kitada M., Wakao S., et al. Committed neural progenitor cells derived from genetically modified bone marrow stromal cells ameliorate deficits in a rat model of stroke. J Cereb Blood Flow Metab 2009, 29:1409-1420.
22. Zisa D., Shabbir A., Suzuki G., et al. Vascular endothelial growth factor (VEGF) as a key therapeutic trophic factor in bone marrow mesenchymal stem cell-mediated cardiac repair. Biochem Biophys Res Commun 2009, 390:834-838.
23. Vemuri M.C., Chase L.G., Rao M.S. Mesenchymal stem cell assays and applications. Methods Mol Biol 2011, 698:3-8.
24. Vitacolonna M., Schubert M., Herbert N., et al. Improved T and B cell recovery by the transfer of slowly dividing human hematopoietic stem cells. Leuk Res 2010, 34:622-630.
25. Hegyi B., Sági B., Kovács J., et al. Identical, similar or different? Learning about immunomodulatory function of mesenchymal stem cells isolated from various mouse tissues: Bone marrow, spleen, thymus and aorta wall. Int Immunol 2010, 22:551-559.
26. Bunell B.A., Betancourt A.M., Sullivan D.E. New concepts on the immune modulation mediated by mesenchymal stem cells. Stem Cell Res 2010, 1:34-39.
27. Ye F., Qiao Z.H., Zhu L., et al. Immunoregulatory effect of mesenchymal stem cells on active T lymphocytes. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2008, 16:1116-1120.
28. van der Touw W., Bromberg J.S. Natural killer cells and the immune response in solid organ transplantation. Am J Transplant 2010, 10:1354-1358.
29. Magee C.C., Pascual M. Update in renal transplantation. Arch Intern Med 2004, 164:1373-1388.
30. Knoll G. Trends in kidney transplantation over the past decade. Drugs. 68 (Suppl) 2008, 1:3-10.
31. Loupy A., Suberbielle-Boissel C., Hill G.S., et al. Outcome of subclinical antibody-mediated rejection in kidney transplant recipients with preformed donor-specific antibodies. Am J Transplant 2009, 9:2561-2570.
32. Uchida J., Iwai T., Kato M., et al. A novel approach to successful ABO-incompatible high-titer renal transplantation. Transplant Proc 2008, 40:2285-2288.
33. Kauffman H.M., Stromstad S.A., Sampson D., et al. Randomized steroid therapy of human kidney transplant rejection. Transplant Proc 1979, 11:36-38.
34. Clatworthy M.R., Friend P.J., Calne R.Y., et al. Alemtuzumab (CAMPATH-1H) for the treatment of acute rejection in kidney transplant recipients: long-term follow-up. Transplantation 2009, 87:1092-1095.
35. Kuypers D.R., Le Meur Y., Cantarovich M., et al. Consensus report on therapeutic drug monitoring of mycophenolic acid in solid organ transplantation. Clin J Am Soc Nephrol 2010, 5:341-358.
36. Dierselhuis M., Goulmy E. The relevance of minor histocompatibility antigens in solid organ transplantation. Curr Opin Organ Trans 2009, 14:419-425.
37. Rossignol J., Boyer C., Thinard R., et al. Mesenchymal stem cells induce a weak immune response in the rat striatum after allo or xenotransplantation. J Cell Mol Med 2009, 13:2547-2558.
38. Le Blanc K., Ringdén O. Immunomodulation by mesenchymal stem cells and clinical experience. J Intern Med 2007, 262:509-525.
39. Asari S., Itakura S., Ferreri K., et al. Mesenchymal stem cells suppress B-cell terminal differentiation. Exp Hematol 2009, 37:604-615.
40. Sato K., Ozaki K., Oh I., Meguro A., et al. Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells. Blood 2007, 109:228-234.
41. Spaggiari G.M., Capobianco A., Becchetti S., et al. Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation. Blood 2006, 107:1484-1490.
42. Spaggiari G.M., Abdelrazik H., Becchetti F., et al. MSCs inhibit monocyte-derived DC maturation and function by selectively interfering with the generation of immature DCs: Central role of MSC-derived prostaglandin E2. Blood 2009, 113:6576-6583.
43. Ghannam S., Bouffi C., Djouad F., et al. Immunosuppression by mesenchymal stem cells: Mechanisms and clinical applications. Stem Cell Res Ther 2010, 1:2.
44. Salem H.K., Thiemermann C. Mesenchymal stromal cells: Current understanding and clinical status. Stem Cells 2010, 28:585-596.
45. Zappia E., Casazza S., Pedemonte E., et al. Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood 2005, 106:1755-1761.
46. Ren G., Su J., Zhang L., et al. Species variation in the mechanisms of mesenchymal stem cell-mediated immunosuppression. Stem Cells 2009, 27:1954-1962.
47. Rüster B., Göttig S., Ludwig R.J., et al. Mesenchymal stem cells display coordinated rolling and adhesion behavior on endothelial cells. Blood 2006, 108:3938-3944.
48. Shi Y., Hu G., Su J., et al. Mesenchymal stem cells: A new strategy for immunosuppression and tissue repair. Cell Res 2010, 20:510-518.
49. Knippertz I., Hesse A., Schunder T., et al. Generation of human dendritic cells that simultaneously secrete IL-12 and have migratory capacity by adenoviral gene transfer of hCD40L in combination with IFN-gamma. J Immunother 2009, 32:524-538.
50. Manning E., Pham S., Li S., et al. Interleukin-10 delivery via mesenchymal stem cells: A novel gene therapy approach to prevent lung ischemia-reperfusion injury. Hum Gene Ther 2010, 21:713-727.
51. Patel S.A., Meyer J.R., Greco S.J., et al. Mesenchymal stem cells protect breast cancer cells through regulatory T cells: Role of mesenchymal stem cell-derived TGF-beta. J Immunol 2010, 184:5885-5894.
52. Ramasamy R., Fazekasova H., Lam E.W., et al. Mesenchymal stem cells inhibit dendritic cell differentiation and function by preventing entry into the cell cycle. Transplantation 2007, 83:71-76.
53. Shabbir A., Zisa D., Leiker M., et al. Muscular dystrophy therapy by nonautologous mesenchymal stem cells: Muscle regeneration without immunosuppression and inflammation. Transplantation 2009, 87:1275-1282.
54. Karlsson H., Samarasinghe S., Ball L.M., et al. Mesenchymal stem cells exert differential effects on alloantigen and virus-specific T-cell responses. Blood 2008, 112:532-541.
55. Day C.L., Kaufmann D.E., Kiepiela P., et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 2006, 443:350-354.
56. Schena F., Gambini C., Gregorio A., et al. Interferon-γ-dependent inhibition of B cell activation by bone marrow-derived mesenchymal stem cells in a murine model of systemic lupus erythematosus. Arthritis Rheum 2010, 62:2776-2786.
57. Smirnov S.V., Harbacheuski R., Lewis-Antes, et al. Bone marrow-derived mesenchymal stem cells as a target for cytomegalovirus infection: Implications for hematopoiesis, self-renewal and differentiation potential. Virology 2007, 360:6-16.
58. Ko I.K., Kim B.G., Awadallah A., et al. Targeting improves MSC treatment of inflammatory bowel disease. Mol Ther 2010, 18:1365-1372.
59. Carrion F., Nova E., Ruiz C., et al. Autologous mesenchymal stem cell treatment increased T regulatory cells with no effect on disease activity in two systemic lupus erythematosus patients. Lupus 2010, 19:317-322.
60. Kastrinaki M.C., Papadaki H.A. Mesenchymal stromal cells in rheumatoid arthritis: Biological properties and clinical applications. Curr Stem Cell Res Ther 2009, 4:61-69.
61. Xu G., Zhang L., Ren G., et al. Immunosuppressive properties of cloned bone marrow mesenchymal stem cells. Cell Res 2007, 17:240-248.
62. Mazzanti B., Aldinuccdi A., Biagioli T., et al. Difference in mesenchymal stem cell cytokine profiles between MS patients and healthy donors: Implication for assessment of disease activity and treatment. J Neuroimmunol 2008, 199:142-150.
63. Kucerova L., Matuskova M., Hlubinova K., et al. Tumor cell behaviour modulation by mesenchymal stromal cells. Mol Cancer 2010, 9:129.
64. Le Blanc K., Rasmusson I., Sundberg B., et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 2004, 363:1439-1441.
65. Bey E., Duhamel P., Lataillade J.J., et al. Treatment of radiation burns with surgery and cell therapy. A report of two cases. Bull Acad Natl Med 2007, 191:971-978.
66. Hoogduijn M.J., Popp F.C., Grohnert A., et al. Advancement of mesenchymal stem cell therapy in solid organ transplantation (MISOT). Transplantation 2010, 90:124-126.
67. Choi S.J., Kim J.K., Hwang S.D. Mesenchymal stem cell therapy for chronic renal failure. Expert Opin Biol Ther 2010, 10:1217-1226.
68. Evens A.M., David K.A., Helenowski I., et al. Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: Outcomes and prognostic factors in the modern era. J Clin Oncol 2010, 28:1038-1046.
69. Joo S.Y., Cho K.A., Jung Y.J., et al. Mesenchymal stromal cells inhibit graft-versus-host disease of mice in a dose-dependent manner. Cytotherapy 2010, 12:361-370.
70. Lucchini G., Introna M., Dander E., et al. Platelet-lysate-expanded mesenchymal stromal cells as a salvage therapy for severe resistant graft-versus-host disease in a pediatric population. Biol Blood Marrow Transplant 2010, 16:1293-1301.
71. Aksu A.E., Horibe E., Sacks J., et al. Co-infusion of donor bone marrow with host mesenchymal stem cells treats GVHD and promotes vascularized skin allograft survival in rats. Clin Immunol 2008, 127:348-358.
72. Amemori T., Jendelová P., Růzicková K., et al. Co-transplantation of olfactory ensheathing glia and mesenchymal stromal cells does not have synergistic effects after spinal cord injury in the rat. Cytotherapy 2010, 12:212-225.
73. Inoue S., Popp F.C., Koehl G.E., et al. Immunomodulatory effects of mesenchymal stem cells in a rat organ transplant model. Transplantation 2006, 81:1589-1595.
74. Ryan J.M., Barry F.P., Murphy J.M., et al. Mesenchymal stem cells avoid allogeneic rejection. J Inflammation 2005, 2:8-14.
75. Isobe M., Futamatsu H., Suzuki J. Hepatocyte growth factor: Effects on immune-mediated heart diseases. Trends Cardiovasc Med 2006, 16:188-193.
76. Son K.R., Chung S.Y., Kim H.C., et al. MRI of magnetically labeled mesenchymal stem cells in hepatic failure model. World J Gastroenterol 2010, 16:5611-5615.
77. Starzl T.E., Esquivel C., Gordon R., et al. Pediatric liver transplantation. Transplant Proc 1987, 193230-193235.
78. Liang T.B., Zheng S.S., Wang W.L., et al. Clinical analysis of different periods of liver transplantation at an organ transplantation central. Zhonghua Wai Ke Za Zhi 2003, 41:6-9.
79. Werner M., Keitel R., Sauer H., et al. Antigen-specific rosette inhibition test with autologous serum-A possibility for the detection of blocking factors in chronic rejection of allogeneic orthotopic kidney transplants. Z Exp Chir Transplant Kunstliche organe 1984, 17:188-199.
80. Storb R., Weiden P.L., Sullivan K.M., et al. Second marrow transplants in patients with aplastic anemia rejecting the first graft: use of a conditioning regimen including cyclophosphamide and antithymocyte globulin. Blood 1987, 70:116-121.
81. Murray J.E. The 50th anniversary of the first successful human organ transplant. Rev Invest Clin 2005, 57:118-119.
82. Billingham R.E. The passenger cell concept in transplantation immunology. Cell Immunol 1971, 2:1-12.
83. Williams J.W., Mital D., Chong A., et al. Experiences with leflunomide in solid organ transplantation. Transplantation 2002, 73:358-366.
84. Adorini L., Giarratana N., Penna G. Pharmacological induction of tolerogenic dendritic cells and regulatory T cells. Semin Immunol 2004, 16:127-134.
85. Simmons W.D., Rayhill S.C., Sollinger H.W. Preliminary risk-benefit assessment of mycophenolate mofetil in transplant rejection. Drug Saf 1997, 17:75-92.
86. Tögel F.E., Westenfelder C. Mesenchymal stem cells: A new therapeutic tool for AKI. Nat Rev Nephrol 2010, 6:179-183.
87. Lim J.H., Lee M.H., Yi H.G., et al. Mesenchymal stromal cells for steroid-refractory acute graft-versus-host disease: A report of two cases. Int J Hematol 2010, 92:204-207.
88. Kebriaei P., Isola L., Bahceci E., et al. Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft-versus-host disease. Biol Blood Marrow Transplant 2009, 15:804-811.
89. Buhrmann C., Mobasheri A., Matis U., et al. Curcumin mediated suppression of nuclear factor-kappaB promotes chondrogenic differentiation of mesenchymal stem cells in a high-density co-culture microenvironment. Arthritis Res Ther 2010, 12:R127.
90. Weil B.R., Manukyan M.C., Herrmann J.L., et al. Mesenchymal stem cells attenuate myocardial functional depression and reduce systemic and myocardial inflammation during endotoxemia. Surgery 2010, 148:444-452.
91. Nurmenniemi S., Kuvaja P., Lehtonen S., et al. Toll-like receptor 9 ligands enhance mesenchymal stem cell invasion and expression of matrix metalloprotease-13. Exp Cell Res 2010, 316:2676-2682.
92. Zhang L.S., Liu Q.F., Huang K., et al. Mesenchymal stem cells for treatment of steroid-resistant chronic graft-versus-host disease. Zhonghua Nei Ke Za Zhi 2009, 48:542-546.
93. Toubai T., Paczesny S., Shono Y., et al. Mesenchymal stem cells for treatment and prevention of graft-versus-host disease after allogeneic hematopoietic cell transplantation. Curr Stem Cell Res Ther 2009, 4:252-259.
94. Guo M., Sun Z., Sun Q.Y., et al. A modified haploidentical nonmyeloablative transplantation without T cell depletion for high-risk acute leukemia: successful engraftment and mild GVHD. Biol Blood Marrow Transplant 2009, 15:930-937.
95. Tolar J., Le Blanc K., Keating A., et al. Hitting the right spot with mesenchymal stromal cells (MSCs). Stem Cells 2010, 28:1446-1455.
96. Jones E., Yang X. Mesenchymal stem cells and bone regeneration: Current status. Injury 2011, 42:562-568.
97. Oda N., Kato T.S., Hanatani A., et al. Reversible posterior leukoencephalopathy syndrome (RPLS) in a heart transplant recipient treated by substitution of cyclosporine A with tacrolimus. Intern Med 2010, 49:1013-1016.
98. Vicari-Christensen M., Repper S., Basile S., et al. Tacrolimus: Review of pharmacokinetics, pharmacodynamics, and pharmacogenetics to facilitate practitioners' understanding and offer strategies for educating patients and promoting adherence. Prog Transplant 2009, 19:277-284.
99. Wai L.E., Fujiki M., Takeda S., et al. Rapamycin, but not cyclosporine or FK506, alters natural killer cell function. Transplantation 2008, 85:145-149.
100. Nelson D.R., Soldevila-Pico C., Reed A., et al. Anti-interleukin-2 receptor therapy in combination with mycophenolate mofetil is associated with more severe hepatitis C recurrence after liver transplantation. Liver Transpl 2001, 7:1064-1070.
101. Wang J.W., Liu Y.B., Xu B., et al. The study on immunomodulation of donor mesenchymal stem cells on discordant liver xenotransplantation. Zhonghua Wai Ke Za Zhi 2005, 43:1254-1258.
102. Tjon A.S., Nicolaas J.S., Kwekkeboom J., et al. Increased incidence of early de novo cancer in liver graft recipients treated with cyclosporine: An association with C2 monitoring and recipient age. Liver Transpl 2010, 16:837-846.
103. Popp F.C., Renner P., Eggenhofer E., et al. Mesenchymal stem cells as immunomodulators after liver transplantation. Liver Transpl 2009, 15:1192-1198.
104. Bai L., Lennon D.P., Eaton V., et al. Human bone marrow-derived mesenchymal stem cells induce Th2-polarized immune response and promote endogenous repair in animal models of multiple sclerosis. Glia 2009, 57:1192-1203.
105. Tuby H., Maltz L., Oron U. Implantation of low-level laser irradiated mesenchymal stem cells into the infarcted rat heart is associated with reduction in infarct size and enhanced angiogenesis. Photomed Laser Surg 2009, 27:227-233.
106. Meyer A.K., Maisel M., Hermann A., et al. Restorative approaches in Parkinson's disease: Which cell type wins the race?. J Neurol Sci 2010, 289:93-103.
107. Shi M., Liu Z.W., Wang F.S. Immunomodulatory properties and therapeutic application of mesenchymal stem cells. Clin Exp Immunol 2011, 164:1-8.
108. Tran H.M., Nickerson P.W., Restifo A.C., et al. Distinct mechanisms for the induction and maintenance of allograft tolerance with CTLA4-Fc treatment. J Immunol 1997, 159:2232-2239.
109. Newman R.E., Yoo D., LeRoux M.A., et al. Treatment of inflammatory diseases with mesenchymal stem cells. Inflamm Allergy Drug Targets 2009, 8:110-123.
110. Schurgers E., Kelchtermans H., Mitera T., et al. Discrepancy between the in vitro and in vivo effects of murine mesenchymal stem cells on T-cell proliferation and collagen-induced arthritis. Arthritis Res Ther 2010, 12:R31.
111. Bernardo M.E., Avanzini M.A., Ciccocioppo R., et al. Phenotypical/functional characterization of in vitro-expanded mesenchymal stromal cells from patients with Crohn's disease. Cytotherapy 2009, 11:825-836.
112. van Poll D., Parekkadan B., Cho C.H., et al. Mesenchymal stem cell-derived molecules directly modulate hepatocellular death and regeneration in vitro and in vivo. Hepatology 2008, 47:1634-1643.
113. Yagi H., Soto-Gutierrez A., Kitagawa Y., et al. Bone marrow mesenchymal stromal cells attenuate organ injury induced by LPS and burn. Cell Transplant 2010, 19:823-830.
114. Parekkadan B., van Poll D., Suganuma K., et al. Mesenchymal stem cell-derived molecules reverse fulminant hepatic failure. PLoS One 2007, e941:2.
115. Fung J.J. Hepatology: Themes of liver transplantation. Hepatology 2010, 51:1869-1884.
116. Popp F.C., Eggenhofer E., Renner P., et al. Mesenchymal stem cells can affect solid organ allograft survival. Transplantation 2009, 87:S57-S62.
117. Selmani Z., Naji A., Gaiffe E., et al. HLA-G is a crucial immunosuppressive molecule secreted by adult human mesenchymal stem cells. Transplantation 2009, 87:S62-S66.
118. Cai Y., Huang S.L., Chen H.Q., et al. Effect of intra-bone marrow infusion of allogeneic mesenchymal stem cells on reconstruction of marrow mesenchymal stem cells in rat HSCT models. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2008, 16:1334-1338.
119. Akl A., Luo S., Wood K.J. Induction of transplantation tolerance-The potential of regulatory T cells. Transpl Immunol 2005, 14:225-230.
120. Kaufman M., Shemesh E., Benton T. The adolescent transplant recipient. Pediatr Clin North Am 2010, 57:575-592.
121. Le Blanc K., Frassoni F., Ball L., et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 2008, 371:1579-1586.
122. Pérez-Ilzarbe M., Díez-Campelo M., Aranda P., et al. Comparison of ex vivo expansion culture conditions of mesenchymal stem cells for human cell therapy. Transfusion 2009, 49:1901-1910.
123. von Bonin M., Stölzel F., Goedecke A., et al. Treatment of refractory acute GVHD with third-party MSC expanded in platelet lysate-containing medium. Bone Marrow Transplant 2009, 43:245-251.
124. Krampera M., Cosmi L., Angeli R., et al. Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells 2006, 24:386-398.
125. Pal R., Venkataramana N.K., Bansal A., et al. Ex vivo-expanded autologous bone marrow-derived mesenchymal stromal cells in human spinal cord injury/paraplegia: A pilot clinical study. Cytotherapy 2009, 11:897-911.
126. Beggs K.J., Lyubimov A., Borneman J.N., et al. Immunologic consequences of multiple, high-dose administration of allogeneic mesenchymal stem cells to baboons. Cell Transplant 2006, 15:711-721.
127. Liska V., Slowik P., Eggenhofer E., et al. Intraportal injection of porcine multipotent mesenchymal stromal cells augments liver regeneration after portal vein embolization. In Vivo 2009, 23:229-235.
128. Koç O.N., Day J., Nieder M., et al. Allogeneic mesenchymal stem cell infusion for treatment of metachromatic leukodystrophy (MLD) and Hurler syndrome (MPS-IH). Bone Marrow Transplant 2002, 30:215-222.
129. Hamidouche Z., Fromigué O., Ringe J., et al. Crosstalks between integrin alpha 5 and IGF2/IGFBP2 signalling trigger human bone marrow-derived mesenchymal stromal osteogenic differentiation. BMC Cell Biol 2010, 11:44.
130. Lepski G., Jannes C.E., Maciaczyk J., et al. Limited Ca2+ and PKA-pathway dependent neurogenic differentiation of human adult mesenchymal stem cells as compared to fetal neuronal stem cells. Exp Cell Res 2010, 316:216-231.
131. Kalajzic I., Stover M.L., Liu P., et al. Use of VSV-G pseudotyped retroviral vectors to target murine osteoprogenitor cells. Stem Cell Rev Virology 2001, 284:37-45.
132. Pessina A., Bonomi A., Coccè V., et al. Assessment of human herpesvirus-6 infection in mesenchymal stromal cells ex vivo expanded for clinical use. Transpl Infect Dis 2009, 11:491-496.
133. Takakura Y., Yamaguchi N., Nakagaki T., et al. Bone marrow stroma cells are susceptible to prion infection. Biochem Biophys Res Commun 2008, 377:957-961.
134. Hong X., Nelson K.K., deCarvalho A.C., et al. Heparanase expression of glioma in human and animal models. Neurosurgery 2009, 64:1139-1146.
135. Cakouros D., Raices R.M., Gronthos S., et al. Twist-ing cell fate: mechanistic insights into the role of twist in lineage specification/differentiation and tumorigenesis. J Cell Biochem 2010, 110:1288-1298.
136. Wang S.S., Asfaha S., Okumura T., et al. Fibroblastic colony-forming unit bone marrow cells delay progression to gastric dysplasia in a helicobacter model of gastric tumorigenesis. Stem Cells 2009, 27:2301-2311.